CN115443288A - 一种免疫球蛋白降解酶IdeE的突变体 - Google Patents

一种免疫球蛋白降解酶IdeE的突变体 Download PDF

Info

Publication number
CN115443288A
CN115443288A CN202180013436.2A CN202180013436A CN115443288A CN 115443288 A CN115443288 A CN 115443288A CN 202180013436 A CN202180013436 A CN 202180013436A CN 115443288 A CN115443288 A CN 115443288A
Authority
CN
China
Prior art keywords
mutant
idee
protein
last
degrading enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180013436.2A
Other languages
English (en)
Inventor
刘彦君
王征
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Baoji Pharmaceutical Co ltd
Original Assignee
Shanghai Baoji Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Baoji Pharmaceutical Co ltd filed Critical Shanghai Baoji Pharmaceutical Co ltd
Publication of CN115443288A publication Critical patent/CN115443288A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus

Abstract

提供了一种免疫球蛋白降解酶IdeE的突变体。所述的免疫球蛋白降解酶IdeE包含如序列表中SEQ ID NO：2所示的氨基酸序列；至少对所述氨基酸序列的位置8、10、24、59、97和280中的一位或者多位进行替换后得到所述突变体；所述的突变体的功能至少包含所述免疫球蛋白降解酶IdeE的功能。提供的免疫球蛋白降解酶突变体的活性和热稳定性高于野生型IdeE。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202180013436.2A 2020-06-18 2021-06-18 一种免疫球蛋白降解酶IdeE的突变体 Pending CN115443288A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010557830X 2020-06-18
CN202010557830 2020-06-18
PCT/CN2021/100844 WO2021254479A1 (zh) 2020-06-18 2021-06-18 一种免疫球蛋白降解酶IdeE的突变体

Publications (1)

Publication Number Publication Date
CN115443288A true CN115443288A (zh) 2022-12-06

Family

ID=79268498

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180013436.2A Pending CN115443288A (zh) 2020-06-18 2021-06-18 一种免疫球蛋白降解酶IdeE的突变体

Country Status (5)

Country Link
US (1) US20230364207A1 (zh)
EP (1) EP4169934A1 (zh)
JP (1) JP2023532219A (zh)
CN (1) CN115443288A (zh)
WO (1) WO2021254479A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023116817A1 (zh) * 2021-12-22 2023-06-29 上海宝济药业有限公司 一种免疫球蛋白降解酶IdeE的突变体的用途
CN114875003A (zh) * 2022-04-06 2022-08-09 浙江大学 一种短链脱氢酶的突变体、编码基因及编码基因获得方法、突变体的应用
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020403A1 (en) * 2007-12-13 2011-01-27 Bengt Guss immunizing composition
CN103068838A (zh) * 2010-05-26 2013-04-24 英特瓦克公司 基于重组蛋白的抗链球菌感染疫苗
AU2016294206A1 (en) * 2015-07-16 2018-02-08 Daiichi Sankyo Company, Limited Novel endos mutant enzyme
US20180170974A1 (en) * 2015-07-09 2018-06-21 Intervacc Ab Vaccine against s. suis infection
US20190262434A1 (en) * 2016-11-16 2019-08-29 University Of Florida Research Foundation, Inc. Immunoglobulin proteases, compositions, and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
CA3013527C (en) * 2016-02-04 2023-09-05 Genovis Ab New streptococcal proteases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020403A1 (en) * 2007-12-13 2011-01-27 Bengt Guss immunizing composition
CN102026658A (zh) * 2007-12-13 2011-04-20 英特瓦克公司 改进的免疫组合物
CN103068838A (zh) * 2010-05-26 2013-04-24 英特瓦克公司 基于重组蛋白的抗链球菌感染疫苗
US20180170974A1 (en) * 2015-07-09 2018-06-21 Intervacc Ab Vaccine against s. suis infection
AU2016294206A1 (en) * 2015-07-16 2018-02-08 Daiichi Sankyo Company, Limited Novel endos mutant enzyme
US20190262434A1 (en) * 2016-11-16 2019-08-29 University Of Florida Research Foundation, Inc. Immunoglobulin proteases, compositions, and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"IgG endopeptidase [Streptococcus equi]", NCBI REFERENCE SEQUENCE：WP_012678049.1 *
"IgG-degrading enzyme/Mac-1 IdeZ[Streptococcus equi]", NCBI REFERENCE SEQUENCE：WP_012515503.1 *
JONAS LANNERGARD 等: "IdeE，an IgG-endopeptidase of Streptococcus equi ssp. equi", FEMS MICROBIOL. LETT., vol. 262, pages 230 - 235, XP055002195, DOI: 10.1111/j.1574-6968.2006.00404.x *
NCBI: "IdeS/Mac family cysteine endopeptidase [Streptococcus equi]", GENBANK蛋白序列数据库 *

Also Published As

Publication number Publication date
US20230364207A1 (en) 2023-11-16
WO2021254479A1 (zh) 2021-12-23
JP2023532219A (ja) 2023-07-27
EP4169934A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
CN115443288A (zh) 一种免疫球蛋白降解酶IdeE的突变体
EP3253783B1 (en) Signalling system
EP3185875B1 (en) Signalling system
CA3055202A1 (en) Cd19 compositions and methods for immunotherapy
CA3161450A1 (en) Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
CA3191433A1 (en) Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
EP4269438A2 (en) Oncolytic virus and method
US20220119824A1 (en) Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
US10172894B2 (en) RNA viruses for immunovirotherapy
CN112739359A (zh) Apmv及其用于治疗癌症的用途
WO2021069806A1 (en) An oncolytic virus vector coding for variant interleukin-2 (vil-2) polypeptide
US20230303684A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
CN113597319A (zh) 用核酸酶融合蛋白治疗干燥症
WO2023116817A1 (zh) 一种免疫球蛋白降解酶IdeE的突变体的用途
US20220154136A1 (en) Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
US20230355722A1 (en) Treatment of sjogren’s syndrome with nuclease fusion proteins
Pflumm Development of a novel SARS-CoV-2 Vaccination Strategy with a monomeric Spike Designer Antigen to prime efficient Antibody Responses in aged Mice
CA3174248A1 (en) Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
CA3172530A1 (en) Ror1 targeting chimeric antigen receptor
WO2022260968A1 (en) Compositions and methods for activating natural killer cells
NZ791667A (en) Adenovirus armed with bispecific T-cell activator

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: No. 28 Luoxin Road, Baoshan District, Shanghai, 201908

Applicant after: Shanghai Baoji Pharmaceutical Co.,Ltd.

Address before: 200942 room a1002, building 3, No. 2288, Shitai Road, Baoshan District, Shanghai

Applicant before: Shanghai Baoji Pharmaceutical Co.,Ltd.

CB02 Change of applicant information